Pentadeca Arginate (PDA) for Recovery
Arginate-salt analog of BPC-157 developed for improved injection stability and tissue repair.
Why Pentadeca Arginate (PDA) for recovery?
Pentadeca Arginate (PDA) is a 15-amino-acid peptide derived from the BPC-157 sequence and complexed with an arginate salt for greater stability and longer shelf life than BPC-157 acetate. Marketed as a research-grade alternative as compounding pharmacies pivoted away from BPC-157 after the FDA's 2023 503A removal. Human trial evidence is limited.
Recovery context: Accelerating soft-tissue, tendon, gut, and post-training repair. Pentadeca Arginate (PDA) fits this goal because its category (Recovery) and benefit profile align with the underlying mechanism.
Benefits relevant to recovery
- Tendon and ligament healing
- Anti-inflammatory
Reference dosing by bodyweight
Anchored to the most-cited research dose (250 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 156–211 mcg |
| 60–75 kg / 132–165 lb | 191–259 mcg |
| 75–90 kg / 165–198 lb | 234–316 mcg |
| 90–105 kg / 198–231 lb | 276–374 mcg |
| >105 kg / >231 lb | 319–431 mcg |
Side effects to weigh against recovery benefit
- Injection-site irritation
- Limited human trial data
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.